Special Sessions are available to view on-demand from October 18 - December 31, 2021.
G-CAN Early Career Investigator Virtual Poster Sessions
| Name | Speakers | Virtual Session Link |
|---|---|---|
| III.01 - Ultrasonography in the Prediction of Gout Flares: A 12-Month Prospective Observational Study | Edoardo Cipolletta, MD | Enter Session |
| III.02 - Genetic Effects on the Transition from Hyperuricemia to Gout | Nicholas Sumpter | Enter Session |
| III.03 - Association of Acidic Urine pH with Impaired Renal Function in Gout Patients | Jie Lu, MD, PhD | Enter Session |
| III.04 - The Role of Calcium Crystals in Osteoarthritis and Chondrocalcinosis | SINA STÜCKER | Enter Session |
| III.05 - Polynesian-Specific Missense Variants Associate with Gout Risk | Megan Leask, PhD | Enter Session |
| III.06 - Inflammatory Potential of Diets and Risk of Incident Gout in US Women and Men: Three Prospective Cohort Studies | Natalie McCormick, PhD | Enter Session |
| III.07 - Gout and Mitochondrial DNA Copy Number in People of European Ancestry | Rachel Dickerson | Enter Session |
| III.08 - Proposal of More Practical Diagnosis of Renal Hyperuricemia: Revealed by Genetic Studies of Nonfunctional Variants of URAT1/SLC22A12 among 30,685 Japanese Individuals | Yusuke Kawamura, MD | Enter Session |
| III.09 - Ultrasound and Conventional Radiography of the Knee in Calcium Pyrophosphate Deposition Disease, Alone or Combined? | Silvia Sirotti, MD | Enter Session |
| III.10 - Development and Validation of an Emergency Department Electronic Medical Record Gout Flare Alert | Lesley Jackson, MD | Enter Session |
| III.11 - What Represents Treatment Efficacy in Long-Term Studies of Gout Flare Prevention? An Interview Study of People with Gout | Jeremy Holyer | Enter Session |
| III.12 - Correlation Between the Urinary Glucose Excretion and Hyperuricemia in the Male Patients with Type 2 Diabetes: A Cross-Sectional Study | Min Yang, MM | Enter Session |
| III.13 - Association of NLRP3 Inflammasome Gene Polymorphisms with the Susceptibility of Gout | Denise Clavijo-Cornejo, PhD | Enter Session |
| III.14 - Evaluation of a 12-Week Allopurinol-Lowering Therapy in Combination with the Non-Steroidal Anti-Inflammatory Drug Meloxicam in Patients with Chronic Gout | Margarita Gromova, PhD | Enter Session |
| III.15 - Septic Arthritis Versus CPPD - Getting the Diagnosis Right | Sharon Cowley | Enter Session |
| III.16 - Urate Lowering Therapeutics; Past and Future | Christopher Jenkins, MD | Enter Session |